跳转至内容
Merck
CN

Y0000461

托拉塞米

European Pharmacopoeia (EP) Reference Standard

别名:

Torsemide, Demadex, N-[[(1-Methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H20N4O3S
CAS号:
分子量:
348.42
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

torasemide

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cccc(C)c2

InChI

1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

InChI key

NGBFQHCMQULJNZ-UHFFFAOYSA-N

基因信息

human ... SLC12A1(6557)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Torasemide anhydrous EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Torsemide is a loop diuretic and inhibitor of the Na+/K+/2Cl- carrier system.
Torsemide is a loop diuretic of the pyridine-sulfonylurea class with antialdosteronergic properties and inhibitor of the Na+/K+/2Cl- carrier system.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazardExclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2 - Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Hitesh B Patel et al.
Journal of AOAC International, 94(1), 143-149 (2011-03-12)
A simple RP-ultra-performance LC method was developed and validated for determination of impurities related to torsemide tablets. The rapid method provided adequate separation of all known related impurities and degradation products. Separation was achieved on a Zorbax SB-C18 column (50
Zarko Jovic et al.
Journal of chromatographic science, 50(4), 324-334 (2012-03-13)
Complete evaluation of chromatographic behavior and establishment of optimal experimental conditions for determination of torasemide and its four impurities are determined by experimental design. Fractional factorial and 3(n) full factorial design were employed for efficient and rapid optimization of liquid
Carmen Acuña
Drugs of today (Barcelona, Spain : 1998), 46 Suppl E, 1-15 (2010-10-12)
Chronic heart failure (CHF) is the cause of significant morbimortality all over the world and its incidence and prevalence are increasing. Fluid retention and volume overload are responsible of large part of morbility related to heart failure. There are a
[Frequent drug interactions in old age].
C C Wagner et al.
Praxis, 98(21), 1185-1190 (2009-10-22)
Gordon D Peddle et al.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 14(1), 253-259 (2012-03-01)
Diuretic therapy reduces preload and relieves congestion secondary to cardiac dysfunction. Torsemide (torasemide) is a loop diuretic with longer duration of action, decreased susceptibility to diuretic resistance, and adjunctive aldosterone antagonist properties compared with furosemide. We hypothesized that torsemide would

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门